DIn a potentially transformative step forward for cannabis access in the United Kingdom, major pharmacy chain Boots said Monday it would start prescribing medical cannabis oil for several conditions.
First reported by talk-radio channel LBC, the offer of relatively affordable medical cannabis access at Boots’ roughly 1,800 locations in the country could supercharge the industry in the U.K., which has lagged behind other countries for years.
It’s the first time a major pharmacy chain in the country has jumped into the cannabis sector.
Is medical cannabis legal in the UK?
According to LBC, Boots’ online prescription service SureLeaf will offer prescriptions for adults over 25 suffering from chronic pain, insomnia or anxiety.
That could potentially offer medical cannabis to millions of Britons, far more than the roughly 120,00 people currently licensed to use the drug in the country.
Patients will have to have pursued other remedies first before receiving doctor’s permission to try cannabis oil or flower for a period of 28 days.
The “lowest dosage” will cost patients as little as £40 (roughly $52 U.S.). Offerings will include Boots SureLeaf-branded high-THC cannabis flower as well as high-CBD oil.
Subscribe to the MJBiz Factbook
Exclusive industry data and analysis to help you make informed business decisions and avoid costly missteps. All the facts, none of the hype.
What you will get:
- Monthly and quarterly updates, with new data & insights
- Financial forecasts + capital investment trends
- State-by-state guide to regulations, taxes & market opportunities
- Annual survey of cannabis businesses
- Consumer insights
- And more!
In a statement to LBC, Boots Chief Healthcare Officer Jamie Kerruish said the company is “committed to making healthcare more accessible and helping people find the right support for their individual needs.”
“Millions of people live with ongoing pain, and for some, conventional treatments do not provide adequate symptom relief,” Kerruish added, as per LBC.
“Medical cannabis is a specialist area of healthcare and, through SureLeaf, we’re giving eligible patients another treatment option to consider, supported by clinical expertise and robust ongoing care.”
How many medical cannabis patients are there in the UK?
Boots, one of the oldest and best-known retail pharmacy chains in the country, was sold last month to the Toronto-based Weston family for a reported $8.9 billion.
Canada was the first country to legalize adult-use cannabis nationally.
And Canadian licensed cannabis producers that have long grown far more cannabis that can be sold domestically are eager for new markets.
Ambitious multinational cannabis companies are also eager for expansion opportunities in Europe and beyond as federal cannabis reform in the U.S. continues to move slowly.
Medical cannabis access in the United Kingdom has been legal since 2018, but a combination of official governmental reluctance and high cost on the private market have severely limited what could be a robust national market.
How big is the medical cannabis market in the UK?
The National Health Service, the U.K.’s public healthcare option, has offered roughly 20,000 cannabis prescriptions, according to Cannabis Europa.
Access is generally limited to severely ill individuals seeking relief from rare epilepsy, the effects of chemotherapy, or multiple sclerosis.
Costly private clinics have offered another 100,000 prescriptions. Patients can access cannabis oil and flower exported from several countries, including the Netherlands and Canada.
Despite these restrictions, prior to Monday’s announcement, Canadian licensed cannabis producers had been demonstrating interest in entering the UK flower market.


